Study of CHS-114 in Participants With Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
In brief
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Key facts
- Study ID
- NCT05635643
- Run by
- Coherus Oncology, Inc.
- People needed
- 87
- Starts
- 2022-12-15
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2026-07-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Washington/Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
- University of Cincinnati — Cincinnati, Ohio, United States (enrolling)
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States (enrolling)
- START- San Antonio — San Antonio, Texas, United States (enrolling)
- START Mountain — West Valley City, Utah, United States (enrolling)
- Stanford Cancer Center — Palo Alto, California, United States (enrolling)
- Emory Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
- University of Louisville — Louisville, Kentucky, United States (enrolling)
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland, United States (enrolling)
- University of Michigan — Ann Arbor, Michigan, United States (enrolling)
- Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center — Detroit, Michigan, United States (enrolling)
- Washington University — St Louis, Missouri, United States (enrolling)
- FOMAT Medical Research — Oxnard, California, United States
- Hope & Healing Cancer Services — Hinsdale, Illinois, United States
- SCRI Lake Nona DDU (FL Cancer Specialists) — Orlando, Florida, United States
- Hoag Memorial Hospital — Newport Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.